Impeccable Qualities of Dr. Imran Haque

When in an interview when Dr. Imran was asked about where the idea of his business came from,  He says that as an upcoming and young doctor working for an internal medicine practice which was hospital-owned, Dr. Imran Haque recognized a great opportunity to grow the horizons of his community by offering services medically that are not offered at the local level. He says that with the encouraging feedback that he received from the patients who were satisfied with services, he felt inspired to revive the dying principle in the community of medical.

When he was asked on what brings his ideas to life, Imran says that it requires diligence, hard work, financial means and thorough research to bring any worthy idea to life. He continues to say that being patient and organized also is necessary to achieve success. He also says that he highly believes that creating symbiotic relationships and networking with other people in different professionals can assist a great deal to ensure success.

When he was asked on what entrepreneurial habit makes him more productive, Imran says that over many years, he has practiced his ability to multi-task to a point of making it a habit. He continues to say that his ability to multi-task is a necessity to him in his daily routine like breathing. He says his multi-tasking ability has become amazingly above average and that has enabled him to be such a great and productive entrepreneur.

Dr. Imran is a specialist in internal medicine located in Asheboro in North Carolina. 1998 is the time when he graduated from the university with honors. By having over 19 years of varied experience, specifically in internal medicine, Dr. Imran affiliates with a lot of hospitals including High point regional hospital, Southeastern Regional Medical center, First health Montgomery Memorial Hospital, Hugh Chatham Memorial Hospital and Randolph and highly cooperates with other specialists and doctors in the medical group Horizon Internal medicine. Dr. Imran has for more than 15 years been treating patients who suffer from different illnesses and his experience has enabled him to get a great level of expertise that he utilizes to deal with the high range of medical examinations and illnesses.

Amicus Therapeutics, Lysosomal Storage Diseases, and How It’s Helping

Fortunately for modern human society, the former threats of many illnesses and ailments that used to threaten peoples’ lives – think smallpox, measles, polio, chicken pox – are long gone, for the most part, thanks to the research and practice of medicine. These ailments were some of the world’s most popular, spurring scientists across the globe to take a collective hand in dealing with them. However, fortunately-unfortunately, some diseases and ailments that are highly problematic don’t affect enough people to make it economically feasible for pharmaceutical giants to develop, research, test, market, and produce treatments or cures for.

amicus1

These diseases are called orphan diseases. Several years following the turn of the millennium, Amicus Therapeutics began researching treatments for orphan diseases, mostly those called lysosomal storage diseases, in which microscopic human cells that break down food and other molecules don’t have enzymes that are powerful enough to do the jobs they’re designed to carry out. This results in a host of health problems.

 

Fabry disease is arguably the most popular lysosomal storage disease Amicus Therapeutics has worked on thus far, featuring the painful, quality of life-reducing symptoms of foot and hand pain, hundreds of red spots located on peoples’ torsos, tinnitus, failure to push out ample sweat, lower-quality hearing and eyesight, among other pesky – sometimes downright terrible – symptoms.

 

Fortunately for the few people suffering from Fabry disease, Amicus Therapeutics got migalastat – brand name Galafold – approved for use in Australia just last month (GCReport). This, combined with other approvals and advancements in clinical trials and studies, has spurred high growth in the stock price of Amicus Therapeutics, rising as much as 178% since January 1st, 2017.

 

Amicus Therapeutics was created in tranquil, rural Cranbury, New Jersey, over fifteen years ago in February of 2002 (http://releasefact.com/2017/08/amicus-therapeutics-funds-its-ground-breaking-new-treatment/). In 2007, Amicus Therapeutics “went public,” meaning its stock was available for sale on major stock exchanges, particularly with the NASDAQ trading symbol of FOLD. Amicus Therapeutics currently holds an impressive 900-plus million dollars’ worth of assets, as of its most recent release of financial statements, per June of 2017.